National Institutes of Health (NIH)

WPF submitted comments regarding how commercially available information (CAI)  — also known as data broker data — will be handled by U.S. Executive Agencies. The Request for Information from OMB was an important opportunity to comment on a topic that has only rarely been opened for public comment. OMB Request for Information regarding Executive Branch

The World Privacy Forum filed detailed comments regarding draft guidance on privacy and medical research to the U.S. Department of Health and Human Services and the U.S. Food and Drug Administration. The proposed guidance, Facilitating Understanding in Informed Consent, is related to consent for human subject research (medical research) and is particularly important. Currently, models of consent are in the process of going digital, which has created a number of challenging problems to solve. In the comments, WPF had several recommendations to improve consent and privacy.

Medical privacy | NCVHS | HIPAA — The World Privacy Forum has sent a letter to Dr. Simon P. Cohn, Chairman of the National Committee on Vital and Health Statistics, supporting the Committee’s formal conclusion that all entities that create, compile, store, transmit, or use personally identifiable health information should be covered by a federal privacy law. More needs to be done about health care data that is left unprotected by HIPAA. The Forum’s letter included a discussion of two HHS programs that operate outside of HIPAA: FDA RiskMAPS, and the National Institutes of Health, which is not a covered entity under HIPAA.

The World Privacy Forum believes that the capability of identifying individuals from subsets of genetic information will expand greatly in the future. In public comments filed with the National Institutes of Health on pharmacogenomics (PGx) research, or research using genetic information to create highly personalized medicine, the World Privacy Forum recommended that all research activities that involve any type of patient-specific genetic information be required to have certificates of confidentiality, whether that information appears identifiable or not. The WPF also urged the NIH to require strong data use agreements to protect individuals’ privacy. The WPF also urged NIH and the Department of Health and Human Services to reinstate the position of “privacy advocate” so as to provide oversight in this area. Read the comments (PDF). For more information, see the genetic section of the WPF Medical Privacy Page.

Genetic privacy — Genome-wide association studies present complex and challenging privacy issues. The National Institutes of Health, in a published request for information, asked for public comment on its proposed policy regarding its support and management of a central genomic repository for genome-wide association studies. In comments filed with the National Institutes of Health, the World Privacy Forum raised concerns about the proposed NIH policy in the specific areas of genetic identifiability, secondary uses of the genetic data, oversight, legal protections, and informed consent.